http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 09 Mar 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Kyntra+Bio+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26128731.html <p>SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company&apos;s corporate and financial performance.</p> <p><strong>Conference Call and Webcast Presentation</strong><br></br>Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&amp;A session will follow the brief presentation. Interested http://www.streetinsider.com/Press+Releases/Kyntra+Bio+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26128731.html Mon, 09 Mar 2026 07:00:00 -0400 KYNB O.00176464 http://www.streetinsider.com/Press+Releases/Kyntra+Bio+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26128731.html <p>SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company&apos;s corporate and financial performance.</p> <p><strong>Conference Call and Webcast Presentation</strong><br></br>Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&amp;A session will follow the brief presentation. Interested http://www.streetinsider.com/Press+Releases/Kyntra+Bio+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26128731.html Mon, 09 Mar 2026 07:00:00 -0400 KYNB O.00176464 http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26128731.html <p>SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company&apos;s corporate and financial performance.</p> <p><strong>Conference Call and Webcast Presentation</strong><br></br>Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&amp;A session will follow the brief presentation. Interested http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26128731.html Mon, 09 Mar 2026 07:00:00 -0400 KYNB O.00176464 http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26128731.html <p>SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company&apos;s corporate and financial performance.</p> <p><strong>Conference Call and Webcast Presentation</strong><br></br>Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&amp;A session will follow the brief presentation. Interested http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+to+Report+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26128731.html Mon, 09 Mar 2026 07:00:00 -0400 KYNB O.00176464 http://www.streetinsider.com/FDA/Kyntra+Bio+reports+positive+results+from+prostate+cancer+drug+trial/26044540.html <p>Kyntra Bio (NASDAQ: KYNB) announced that data from an investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide for metastatic castration-resistant prostate cancer will be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, scheduled for February 26-28, 2026 in San Francisco.</p> <p>The study included 44 patients with progressive metastatic castration-resistant prostate cancer. The combination therapy demonstrated a median radiographic progression-free survival of 7.0 months in the overall study cohort. Patients who progressed on only one prior androgen receptor pathway inhibitor showed a median radiographic progression-free survival of 10.1 months.</p> <p>The composite response rate was 21% in the http://www.streetinsider.com/FDA/Kyntra+Bio+reports+positive+results+from+prostate+cancer+drug+trial/26044540.html Mon, 23 Feb 2026 17:10:09 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/FDA/Kyntra+Bio+reports+positive+results+from+prostate+cancer+drug+trial/26044540.html <p>Kyntra Bio (NASDAQ: KYNB) announced that data from an investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide for metastatic castration-resistant prostate cancer will be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, scheduled for February 26-28, 2026 in San Francisco.</p> <p>The study included 44 patients with progressive metastatic castration-resistant prostate cancer. The combination therapy demonstrated a median radiographic progression-free survival of 7.0 months in the overall study cohort. Patients who progressed on only one prior androgen receptor pathway inhibitor showed a median radiographic progression-free survival of 10.1 months.</p> <p>The composite response rate was 21% in the http://www.streetinsider.com/FDA/Kyntra+Bio+reports+positive+results+from+prostate+cancer+drug+trial/26044540.html Mon, 23 Feb 2026 17:10:09 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/FDA/Kyntra+Bio+reports+positive+results+from+prostate+cancer+drug+trial/26044540.html <p>Kyntra Bio (NASDAQ: KYNB) announced that data from an investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide for metastatic castration-resistant prostate cancer will be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, scheduled for February 26-28, 2026 in San Francisco.</p> <p>The study included 44 patients with progressive metastatic castration-resistant prostate cancer. The combination therapy demonstrated a median radiographic progression-free survival of 7.0 months in the overall study cohort. Patients who progressed on only one prior androgen receptor pathway inhibitor showed a median radiographic progression-free survival of 10.1 months.</p> <p>The composite response rate was 21% in the http://www.streetinsider.com/FDA/Kyntra+Bio+reports+positive+results+from+prostate+cancer+drug+trial/26044540.html Mon, 23 Feb 2026 17:10:09 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/FDA/Kyntra+Bio+reports+positive+results+from+prostate+cancer+drug+trial/26044540.html <p>Kyntra Bio (NASDAQ: KYNB) announced that data from an investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide for metastatic castration-resistant prostate cancer will be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, scheduled for February 26-28, 2026 in San Francisco.</p> <p>The study included 44 patients with progressive metastatic castration-resistant prostate cancer. The combination therapy demonstrated a median radiographic progression-free survival of 7.0 months in the overall study cohort. Patients who progressed on only one prior androgen receptor pathway inhibitor showed a median radiographic progression-free survival of 10.1 months.</p> <p>The composite response rate was 21% in the http://www.streetinsider.com/FDA/Kyntra+Bio+reports+positive+results+from+prostate+cancer+drug+trial/26044540.html Mon, 23 Feb 2026 17:10:09 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/FDA/Kyntra+Bio+reports+positive+results+from+prostate+cancer+drug+trial/26044540.html <p>Kyntra Bio (NASDAQ: KYNB) announced that data from an investigator-sponsored Phase 1b/2 study of FG-3246 in combination with enzalutamide for metastatic castration-resistant prostate cancer will be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, scheduled for February 26-28, 2026 in San Francisco.</p> <p>The study included 44 patients with progressive metastatic castration-resistant prostate cancer. The combination therapy demonstrated a median radiographic progression-free survival of 7.0 months in the overall study cohort. Patients who progressed on only one prior androgen receptor pathway inhibitor showed a median radiographic progression-free survival of 10.1 months.</p> <p>The composite response rate was 21% in the http://www.streetinsider.com/FDA/Kyntra+Bio+reports+positive+results+from+prostate+cancer+drug+trial/26044540.html Mon, 23 Feb 2026 17:10:09 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/Press+Releases/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html <ul><li style="text-align:justify;"><em>FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPI</em></li><li style="text-align:justify;"><em>Higher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection </em></li><li style="text-align:justify;"><em>Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trial</em></li><li style="text-align:justify;"><em>Results http://www.streetinsider.com/Press+Releases/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html Mon, 23 Feb 2026 17:10:00 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/Press+Releases/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html <ul><li style="text-align:justify;"><em>FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPI</em></li><li style="text-align:justify;"><em>Higher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection </em></li><li style="text-align:justify;"><em>Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trial</em></li><li style="text-align:justify;"><em>Results http://www.streetinsider.com/Press+Releases/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html Mon, 23 Feb 2026 17:10:00 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/Press+Releases/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html <ul><li style="text-align:justify;"><em>FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPI</em></li><li style="text-align:justify;"><em>Higher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection </em></li><li style="text-align:justify;"><em>Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trial</em></li><li style="text-align:justify;"><em>Results http://www.streetinsider.com/Press+Releases/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html Mon, 23 Feb 2026 17:10:00 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/Press+Releases/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html <ul><li style="text-align:justify;"><em>FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPI</em></li><li style="text-align:justify;"><em>Higher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection </em></li><li style="text-align:justify;"><em>Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trial</em></li><li style="text-align:justify;"><em>Results http://www.streetinsider.com/Press+Releases/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html Mon, 23 Feb 2026 17:10:00 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/Press+Releases/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html <ul><li style="text-align:justify;"><em>FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPI</em></li><li style="text-align:justify;"><em>Higher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection </em></li><li style="text-align:justify;"><em>Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trial</em></li><li style="text-align:justify;"><em>Results http://www.streetinsider.com/Press+Releases/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html Mon, 23 Feb 2026 17:10:00 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html <ul><li style="text-align:justify;"><em>FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPI</em></li><li style="text-align:justify;"><em>Higher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection </em></li><li style="text-align:justify;"><em>Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trial</em></li><li style="text-align:justify;"><em>Results http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html Mon, 23 Feb 2026 17:10:00 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html <ul><li style="text-align:justify;"><em>FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPI</em></li><li style="text-align:justify;"><em>Higher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection </em></li><li style="text-align:justify;"><em>Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trial</em></li><li style="text-align:justify;"><em>Results http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html Mon, 23 Feb 2026 17:10:00 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html <ul><li style="text-align:justify;"><em>FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPI</em></li><li style="text-align:justify;"><em>Higher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection </em></li><li style="text-align:justify;"><em>Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trial</em></li><li style="text-align:justify;"><em>Results http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html Mon, 23 Feb 2026 17:10:00 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html <ul><li style="text-align:justify;"><em>FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPI</em></li><li style="text-align:justify;"><em>Higher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection </em></li><li style="text-align:justify;"><em>Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trial</em></li><li style="text-align:justify;"><em>Results http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html Mon, 23 Feb 2026 17:10:00 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html <ul><li style="text-align:justify;"><em>FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPI</em></li><li style="text-align:justify;"><em>Higher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection </em></li><li style="text-align:justify;"><em>Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trial</em></li><li style="text-align:justify;"><em>Results http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+Announces+Positive+Data+from+the+Investigator-Sponsored+Phase+1b2+Study+of+FG-3246+in+Combination+with+Enzalutamide+in+Patients+with+Metastatic+Castration+Resistant+Prostate+Cancer+to+Be+P/26044534.html Mon, 23 Feb 2026 17:10:00 -0400 A.02242875 FGEN KYNB O.00176464 O.05849870 http://www.streetinsider.com/Press+Releases/Kyntra+Bio+to+Participate+in+Upcoming+Investor+Conferences/26012313.html <p align="justify">SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor conferences:</p> <p align="justify"><strong>Oppenheimer 36th Annual Healthcare Life Sciences Conference</strong><br/>Format: Corporate Presentation <br/>Date &amp; Time: Thursday, February 26, 2026, 2:40-3:10 PM ET <br/>Location: Virtual <br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JHyoYy2hUfoFSPKKeHJOsmzB5oF-6UkJ456uaYb2nlXevORdCuQPnMJxm4cePaVUIhBHxmpq09R4G8N0I6JUVS4FnUVydBd9b5f0Hu_L5wJgegNrtNUUR1DtaW4RweBExR-HaIvLmvUoJHRaCM2uJT9wZkAmJkLw_iEwchjqqwL6d2twzKoipf_6JIW_r4jX" rel="nofollow" target="_blank">https://event.summitcast.com/view/</a></p> <p><strong>Leerink Global Healthcare Conference</strong><br/>Format: Corporate Presentation <br/>Date &amp; Time: Wednesday, March 11, 2026, 2:20-2:50 PM ET<br/>Location: Miami, FL <br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JHyoYy2hUfoFSPKKeHJOsmzB5oF-6UkJ456uaYb2nlV1KVfo2nQ_B_PaZFGEzTmdqLGaZFQxMs78SKoC_FXZu6yd7LOwy2yJNorfsOPj1ke3jvAzGMsWnXTreE7CBQ5uLF5QwilgvixxR2EfBrO26JgiBoA-gafEJXG74_I-fEFuBe_w0ZgmnkBxWI0biJuXXKnnxDuIZJ4F7vSHLwzMf19mzbwIa9EY7irOJ1VBSyLToW9q-yGOhouc2H4V5CR0UaH-4u3kiEMQFN9IKxh6_Ny6c0XFAyEmMh0J4dKTbk-MxcugH1gizLRy41qUaZxgQJ5mPTb-pLYMYLWdVaImuzYsVhRU8Bw_9nIScFClsct0B-Qq8nPv4UxTn6YUxB_qkNevd7Cp9LpvfQWRr4uhVz1ktu-85K1B46-1ZTGa910xeQlK80WxX901mH_4aoDjrJoGAZLAOwwtEXxK-uHym48TcFqXGFkBjkM42a4MFb3VQqJDWwKdwn42cHdbFJGkIzGDSCzevy52ngNxmLGUSu5Qh-sEyON5ectw2FhBiPGSzic5PTj3-a6NzlwK1BXr2t8-oBzlIk7I3Y1Is1oZRVUuLFRSV7SAgdBePMGnsicoq0CihUvoT7As1Lbf4vVC11MtThdQGNl-QSFzsq4m8eRs-ADPbjW-7hT4IduSNlncl99FlSIITJy3gXXHqHYQmVsgC1TXYVkNrvFlIDyJPCAMPLRLzS5kfeaYVo2dWdo=" rel="nofollow" target="_blank">https://event.summitcast.com/view/</a></p> <p>Kyntra Bio’s management team will be available for one-on-one meetings during the conferences. http://www.streetinsider.com/Press+Releases/Kyntra+Bio+to+Participate+in+Upcoming+Investor+Conferences/26012313.html Tue, 17 Feb 2026 16:05:00 -0400 KYNB O.00176464 http://www.streetinsider.com/Press+Releases/Kyntra+Bio+to+Participate+in+Upcoming+Investor+Conferences/26012313.html <p align="justify">SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor conferences:</p> <p align="justify"><strong>Oppenheimer 36th Annual Healthcare Life Sciences Conference</strong><br/>Format: Corporate Presentation <br/>Date &amp; Time: Thursday, February 26, 2026, 2:40-3:10 PM ET <br/>Location: Virtual <br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JHyoYy2hUfoFSPKKeHJOsmzB5oF-6UkJ456uaYb2nlXevORdCuQPnMJxm4cePaVUIhBHxmpq09R4G8N0I6JUVS4FnUVydBd9b5f0Hu_L5wJgegNrtNUUR1DtaW4RweBExR-HaIvLmvUoJHRaCM2uJT9wZkAmJkLw_iEwchjqqwL6d2twzKoipf_6JIW_r4jX" rel="nofollow" target="_blank">https://event.summitcast.com/view/</a></p> <p><strong>Leerink Global Healthcare Conference</strong><br/>Format: Corporate Presentation <br/>Date &amp; Time: Wednesday, March 11, 2026, 2:20-2:50 PM ET<br/>Location: Miami, FL <br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JHyoYy2hUfoFSPKKeHJOsmzB5oF-6UkJ456uaYb2nlV1KVfo2nQ_B_PaZFGEzTmdqLGaZFQxMs78SKoC_FXZu6yd7LOwy2yJNorfsOPj1ke3jvAzGMsWnXTreE7CBQ5uLF5QwilgvixxR2EfBrO26JgiBoA-gafEJXG74_I-fEFuBe_w0ZgmnkBxWI0biJuXXKnnxDuIZJ4F7vSHLwzMf19mzbwIa9EY7irOJ1VBSyLToW9q-yGOhouc2H4V5CR0UaH-4u3kiEMQFN9IKxh6_Ny6c0XFAyEmMh0J4dKTbk-MxcugH1gizLRy41qUaZxgQJ5mPTb-pLYMYLWdVaImuzYsVhRU8Bw_9nIScFClsct0B-Qq8nPv4UxTn6YUxB_qkNevd7Cp9LpvfQWRr4uhVz1ktu-85K1B46-1ZTGa910xeQlK80WxX901mH_4aoDjrJoGAZLAOwwtEXxK-uHym48TcFqXGFkBjkM42a4MFb3VQqJDWwKdwn42cHdbFJGkIzGDSCzevy52ngNxmLGUSu5Qh-sEyON5ectw2FhBiPGSzic5PTj3-a6NzlwK1BXr2t8-oBzlIk7I3Y1Is1oZRVUuLFRSV7SAgdBePMGnsicoq0CihUvoT7As1Lbf4vVC11MtThdQGNl-QSFzsq4m8eRs-ADPbjW-7hT4IduSNlncl99FlSIITJy3gXXHqHYQmVsgC1TXYVkNrvFlIDyJPCAMPLRLzS5kfeaYVo2dWdo=" rel="nofollow" target="_blank">https://event.summitcast.com/view/</a></p> <p>Kyntra Bio’s management team will be available for one-on-one meetings during the conferences. http://www.streetinsider.com/Press+Releases/Kyntra+Bio+to+Participate+in+Upcoming+Investor+Conferences/26012313.html Tue, 17 Feb 2026 16:05:00 -0400 KYNB O.00176464 http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+to+Participate+in+Upcoming+Investor+Conferences/26012313.html <p align="justify">SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor conferences:</p> <p align="justify"><strong>Oppenheimer 36th Annual Healthcare Life Sciences Conference</strong><br/>Format: Corporate Presentation <br/>Date &amp; Time: Thursday, February 26, 2026, 2:40-3:10 PM ET <br/>Location: Virtual <br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JHyoYy2hUfoFSPKKeHJOsmzB5oF-6UkJ456uaYb2nlXevORdCuQPnMJxm4cePaVUIhBHxmpq09R4G8N0I6JUVS4FnUVydBd9b5f0Hu_L5wJgegNrtNUUR1DtaW4RweBExR-HaIvLmvUoJHRaCM2uJT9wZkAmJkLw_iEwchjqqwL6d2twzKoipf_6JIW_r4jX" rel="nofollow" target="_blank">https://event.summitcast.com/view/</a></p> <p><strong>Leerink Global Healthcare Conference</strong><br/>Format: Corporate Presentation <br/>Date &amp; Time: Wednesday, March 11, 2026, 2:20-2:50 PM ET<br/>Location: Miami, FL <br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JHyoYy2hUfoFSPKKeHJOsmzB5oF-6UkJ456uaYb2nlV1KVfo2nQ_B_PaZFGEzTmdqLGaZFQxMs78SKoC_FXZu6yd7LOwy2yJNorfsOPj1ke3jvAzGMsWnXTreE7CBQ5uLF5QwilgvixxR2EfBrO26JgiBoA-gafEJXG74_I-fEFuBe_w0ZgmnkBxWI0biJuXXKnnxDuIZJ4F7vSHLwzMf19mzbwIa9EY7irOJ1VBSyLToW9q-yGOhouc2H4V5CR0UaH-4u3kiEMQFN9IKxh6_Ny6c0XFAyEmMh0J4dKTbk-MxcugH1gizLRy41qUaZxgQJ5mPTb-pLYMYLWdVaImuzYsVhRU8Bw_9nIScFClsct0B-Qq8nPv4UxTn6YUxB_qkNevd7Cp9LpvfQWRr4uhVz1ktu-85K1B46-1ZTGa910xeQlK80WxX901mH_4aoDjrJoGAZLAOwwtEXxK-uHym48TcFqXGFkBjkM42a4MFb3VQqJDWwKdwn42cHdbFJGkIzGDSCzevy52ngNxmLGUSu5Qh-sEyON5ectw2FhBiPGSzic5PTj3-a6NzlwK1BXr2t8-oBzlIk7I3Y1Is1oZRVUuLFRSV7SAgdBePMGnsicoq0CihUvoT7As1Lbf4vVC11MtThdQGNl-QSFzsq4m8eRs-ADPbjW-7hT4IduSNlncl99FlSIITJy3gXXHqHYQmVsgC1TXYVkNrvFlIDyJPCAMPLRLzS5kfeaYVo2dWdo=" rel="nofollow" target="_blank">https://event.summitcast.com/view/</a></p> <p>Kyntra Bio’s management team will be available for one-on-one meetings during the conferences. http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+to+Participate+in+Upcoming+Investor+Conferences/26012313.html Tue, 17 Feb 2026 16:05:00 -0400 KYNB O.00176464 http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+to+Participate+in+Upcoming+Investor+Conferences/26012313.html <p align="justify">SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor conferences:</p> <p align="justify"><strong>Oppenheimer 36th Annual Healthcare Life Sciences Conference</strong><br/>Format: Corporate Presentation <br/>Date &amp; Time: Thursday, February 26, 2026, 2:40-3:10 PM ET <br/>Location: Virtual <br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JHyoYy2hUfoFSPKKeHJOsmzB5oF-6UkJ456uaYb2nlXevORdCuQPnMJxm4cePaVUIhBHxmpq09R4G8N0I6JUVS4FnUVydBd9b5f0Hu_L5wJgegNrtNUUR1DtaW4RweBExR-HaIvLmvUoJHRaCM2uJT9wZkAmJkLw_iEwchjqqwL6d2twzKoipf_6JIW_r4jX" rel="nofollow" target="_blank">https://event.summitcast.com/view/</a></p> <p><strong>Leerink Global Healthcare Conference</strong><br/>Format: Corporate Presentation <br/>Date &amp; Time: Wednesday, March 11, 2026, 2:20-2:50 PM ET<br/>Location: Miami, FL <br/>Webcast: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JHyoYy2hUfoFSPKKeHJOsmzB5oF-6UkJ456uaYb2nlV1KVfo2nQ_B_PaZFGEzTmdqLGaZFQxMs78SKoC_FXZu6yd7LOwy2yJNorfsOPj1ke3jvAzGMsWnXTreE7CBQ5uLF5QwilgvixxR2EfBrO26JgiBoA-gafEJXG74_I-fEFuBe_w0ZgmnkBxWI0biJuXXKnnxDuIZJ4F7vSHLwzMf19mzbwIa9EY7irOJ1VBSyLToW9q-yGOhouc2H4V5CR0UaH-4u3kiEMQFN9IKxh6_Ny6c0XFAyEmMh0J4dKTbk-MxcugH1gizLRy41qUaZxgQJ5mPTb-pLYMYLWdVaImuzYsVhRU8Bw_9nIScFClsct0B-Qq8nPv4UxTn6YUxB_qkNevd7Cp9LpvfQWRr4uhVz1ktu-85K1B46-1ZTGa910xeQlK80WxX901mH_4aoDjrJoGAZLAOwwtEXxK-uHym48TcFqXGFkBjkM42a4MFb3VQqJDWwKdwn42cHdbFJGkIzGDSCzevy52ngNxmLGUSu5Qh-sEyON5ectw2FhBiPGSzic5PTj3-a6NzlwK1BXr2t8-oBzlIk7I3Y1Is1oZRVUuLFRSV7SAgdBePMGnsicoq0CihUvoT7As1Lbf4vVC11MtThdQGNl-QSFzsq4m8eRs-ADPbjW-7hT4IduSNlncl99FlSIITJy3gXXHqHYQmVsgC1TXYVkNrvFlIDyJPCAMPLRLzS5kfeaYVo2dWdo=" rel="nofollow" target="_blank">https://event.summitcast.com/view/</a></p> <p>Kyntra Bio’s management team will be available for one-on-one meetings during the conferences. http://www.streetinsider.com/Globe+Newswire/Kyntra+Bio+to+Participate+in+Upcoming+Investor+Conferences/26012313.html Tue, 17 Feb 2026 16:05:00 -0400 KYNB O.00176464